Humana Inc. (HUM) drops on earnings beat, margin deep dive
Humana Inc. (HUM) beat second-quarter EPS and revenue estimates, yet the stock dropped as investors focused on Medicare Advantage margin repair, cost-ratio improvement, and 2027 bid strategy. This deep-dive examines why the earnings beat wasn’t enough to offset longer-term execution risks.
Humana Inc. (HUM) beat second-quarter expectations with EPS of $7.61 and revenue of $40.87B, but the stock fell 5.24% as investors focused on the company’s Medicare Advantage margin repair plan. Management is targeting a sustainable pretax margin of at least 3% in 2028, even as about 600,000 members could face plan exits in 2027. For investors, the quarter confirms operating progress, but the valuation now depends on execution rather than the earnings beat alone.
Humana Inc. (HUM) posted second-quarter EPS of $7.61, topping the $7.26 estimate, while revenue reached $40.87B versus $40.57B expected. Yet HUM drops 5.24% to $368.34 in regular trading on July 29, 2026, as investors weigh the beat against a demanding Medicare Advantage margin repair plan.
Key Takeaways
HUM earnings beat both major estimates: EPS came in at $7.61 versus $7.26 expected, while revenue reached $40.87B versus $40.57B.
Revenue exceeded the $39.65B reported in the first quarter of 2026 and the $32.39B reported in the second quarter of 2025.
CenterWell generated $22.473B of 2025 revenue, up from $19.936B in 2024. The Insurance Segment remained the larger business at $124.563B in 2025.
CFO Celeste Mellet said the consolidated operating cost ratio fell 120 basis points year-over-year. Humana expects a full-year reduction of about 150 basis points.
CEO James Rechtin tied the 2027 Medicare Advantage bid strategy to a sustainable pretax margin of at least 3% in 2028. Humana expects about 600,000 members to face plan exits in 2027.
The analyst consensus remains Hold, with 15 Buy ratings, 27 Hold ratings and 2 Sell ratings. Recent actions still show a wide split, from Wells Fargo's $502 target to a $346.71 average target.
The headline result was solid. Humana delivered $7.61 in EPS, ahead of the $7.26 consensus estimate. Revenue reached $40.87B, beating the $40.57B estimate by $0.30B. The company therefore cleared both top-line and bottom-line hurdles in the quarter.
Revenue also improved against recent reported periods. The second-quarter figure stood above $39.65B in the first quarter of 2026 and $32.39B in the second quarter of 2025. That scale gives Humana a stronger base, although the stock's reaction shows that investors are placing greater weight on margins than on revenue alone.
EPS history remains uneven. Humana reported $10.31 in the first quarter of 2026, a loss of $3.96 in the fourth quarter of 2025, $3.24 in the third quarter of 2025 and $6.27 in the second quarter of 2025. The current beat is encouraging, but the sequence also explains why the market wants proof of durable earnings power rather than a single strong quarter.
The segment data show two different engines. Insurance produced $124.563B of 2025 revenue, compared with $113.764B in 2024. CenterWell generated $22.473B, compared with $19.936B a year earlier. Insurance supplies the scale, while CenterWell provides a smaller but growing platform tied to Humana's broader consumer health care strategy.
The most important cost figure came from the operating model. Mellet reported a 120-basis-point year-over-year decline in the second-quarter consolidated operating cost ratio. Management also expects a full-year reduction of approximately 150 basis points. The company linked those savings to centralized operations, greater outsourcing, vendor changes and automation.
Medical cost trends are running within the 7% to 8% range assumed for 2026, inclusive of medical and pharmacy costs. Humana cited slight favorability in inpatient care, with that benefit concentrated among members using value-based providers. Risk-sharing agreements limit the amount that flows into Humana's financial results, but the company described the data as evidence of broader stabilization in Medicare Advantage trends.
Capital actions add another layer to the financial picture. Humana agreed to sell its minority interest in Gentiva for approximately $900M, with the transaction expected to close in the fourth quarter. The proceeds will largely fund the MaxHealth acquisition. Humana also established $1.5B in contingent capital facilities using pre-capitalized trust securities.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
HUM drops despite the earnings beat. The stock traded at $368.34 during the July 29 regular session, down 5.24%. Volume reached 2,824,029 shares against an average of 1,512,632. The contrast is sharp: the company beat estimates, yet the market marked down the shares as management emphasized plan exits and future margin work.
The consensus rating remains Hold, based on 15 Buy ratings, 27 Holds and 2 Sells. The average analyst price target was $346.71 as of July 22, while Humana's investor-relations estimate showed a median target of $345.49. Both figures sit below the July 29 share price, which places a higher execution burden on the turnaround story.
Recent analyst actions reveal a divided market. Wells Fargo upgraded Humana to Overweight from Equal Weight on July 13 and lifted its price target to $502 from $227. BofA raised its target to $410 on July 20, citing trend data. Deutsche Bank upgraded the stock to Buy from Hold on May 20 and raised its target from $235 to $441.
The cautious side is also visible. RBC Capital downgraded Humana to Sector Perform from a more favorable rating on February 12 and cut its target from $322 to $189. Cantor Fitzgerald raised its target on July 7 after reviewing Medicaid enrollment data and said the attrition environment was largely in line with payer outlooks. The result is a Street that recognizes operational progress but still demands evidence that Medicare Advantage margins can recover.
The HUM earnings call centered on a clear strategic tradeoff. Humana wants to protect membership and improve service, but management is also changing benefits, exiting selected plans and lifting operating efficiency. That approach favors earnings durability over maximum near-term enrollment.
"Today's headlines are, we are pleased with our year-to-date performance, and we continue to be tracking to expectations."
- James Rechtin, CEO, Humana earnings call
Rechtin placed the 2027 bid strategy at the center of the long-term narrative. Humana plans to combine clinical improvements, operating efficiency, benefit adjustments and plan-mix changes to make meaningful progress toward a sustainable 3% pretax margin in 2028. He also said the company remains confident in returning to top-quartile Stars results in bonus year 2028.
"We expect that our approach to 2027 MA bids will drive solid progress against our goal of delivering a sustainable pretax margin of at least 3% in 2028."
- James Rechtin, CEO, Humana earnings call
The CEO also supplied evidence of operational change. Humana centralized utilization management across 11 markets, expanded outsourcing in finance and human resources, optimized information-technology vendors and integrated CarePlus into its core platforms. Rechtin said those efforts produced hundreds of millions of dollars in value during the first half of 2026.
"Our 2Q consolidated operating cost ratio is down 120 basis points year-over-year, and we continue to expect a full year reduction of approximately 150 basis points."
- Celeste Mellet, CFO, Humana earnings call
Mellet supplied the financial framework behind the strategy. Humana expects to double its individual Medicare Advantage pretax margin in 2026, excluding the Stars headwind. For 2027, the company expects meaningful margin expansion, although final results will depend on membership size and composition.
"For 2027, we anticipate these plan exits will impact approximately 600,000 members, though we will work to recapture a significant portion of that volume as we did in 2025."
- Celeste Mellet, CFO, Humana earnings call
That 600,000-member figure is the most direct sign of near-term friction. Humana plans to prioritize higher-performing plans, including plans with greater value-based care penetration. The company also expects to launch a statewide Illinois Medicaid managed-care contract in January 2027. Humana was the only new entrant selected alongside five incumbents.
Bottom Line
Humana Inc. earnings analysis points to a business that is beating estimates while still asking investors to finance a difficult margin reset. The $7.61 EPS beat and 120-basis-point cost improvement support the turnaround, but the 5.24% stock drop shows that the market wants durable Medicare Advantage progress before rewarding HUM with a higher multiple.
+Why did Humana stock fall after beating earnings?
Humana reported Q2 EPS of $7.61 versus the $7.26 estimate and revenue of $40.87B versus $40.57B expected, but shares fell 5.24% to $368.34. Investors were more focused on the company’s Medicare Advantage margin repair plan and the risk tied to future plan exits.
+What were Humana's Q2 2026 earnings and revenue results?
Humana posted second-quarter EPS of $7.61, beating the $7.26 consensus estimate. Revenue came in at $40.87B, above the $40.57B estimate and higher than both Q1 2026 revenue of $39.65B and Q2 2025 revenue of $32.39B.
+What is Humana's margin outlook after the quarter?
Humana said the consolidated operating cost ratio fell 120 basis points year over year in Q2 and expects about a 150-basis-point full-year reduction. Management is targeting a sustainable pretax margin of at least 3% in 2028.
+What is the analyst view on Humana stock right now?
The consensus rating on Humana remains Hold, with 15 Buy ratings, 27 Hold ratings, and 2 Sell ratings. The average analyst price target was $346.71, below the July 29 share price of $368.34, though individual targets range widely.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on HUM?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
